Scientists are on the verge of transforming chronic pain treatment with several breakthrough non-opioid compounds that target specific pain receptors without the addiction risks of traditional painkillers.

At a Glance

• Vertex Pharmaceuticals’ Journavx (suzetrigine) received FDA approval as the first drug in a new class of pain medications that targets sodium channels in the peripheral nervous system
• Yale researchers identified cannabinoids, particularly CBG, as promising candidates for effective pain relief without mind-altering effects
• Scientists have developed several novel compounds that target different pain receptors, including cannabinoid receptor type 1 (CB1) and delta opioid receptors (δOR)
• These alternatives could address the urgent need for safer pain management solutions amid the ongoing opioid crisis
• The non-opioid pain treatment market is expected to grow significantly as research advances and awareness increases

FDA Approves First-of-its-Kind Non-Opioid Pain Medication

In a significant advancement for pain management, the FDA has approved Vertex Pharmaceuticals’ Journavx (suzetrigine), marking a breakthrough in non-opioid pain medication development. This novel drug works by blocking pain signals at their source through targeting sodium channels in the peripheral nervous system, unlike opioids that act on the brain’s pain perception. Journavx 50 mg oral tablets have been approved for treating moderate to severe acute pain in adults and are expected to be available in pharmacies soon.

The approval comes as a response to the urgent need for safer pain treatments. Nearly one-fourth of U.S. adults experienced chronic pain in 2023, with associated costs exceeding $600 billion annually. The opioid crisis has accelerated the shift toward developing non-addictive pain relief alternatives, with pharmaceutical companies intensifying research into novel mechanisms that avoid the dangerous side effects of traditional painkillers.

https://twitter.com/jdotarnold/status/1858628790718464314

Cannabinoids Show Promise for Safe Pain Relief

Yale researchers have identified chemicals in cannabis that may effectively treat chronic pain without mind-altering effects. Their study focused on cannabinoids like CBD, CBG, and CBN, examining how these compounds interact with sodium channels involved in pain transmission. The research revealed that CBG demonstrated particularly strong potential for pain management without the risks associated with traditional treatments like opioids.

The study emphasizes the importance of Nav1.8 as a therapeutic target for developing cannabinoid-based pain treatments. This research builds on growing interest in cannabinoids’ therapeutic potential for addressing chronic pain conditions such as neuropathic pain, arthritis, and inflammatory disorders. By focusing on specific receptors involved in pain perception, these compounds may provide relief with fewer adverse effects.

Novel Compounds Target Specific Pain Receptors

Scientists at Washington University School of Medicine and the University of Health Sciences and Pharmacy have developed a new compound called C6-Quino that targets the delta opioid receptor (δOR). This innovative approach provides pain relief without severe side effects like respiratory depression or seizures commonly associated with traditional opioids. C6-Quino acts as a partial agonist, activating pain relief pathways while minimizing unwanted effects.

In a separate study, researchers developed a non-opioid compound that relieved pain in mice without adverse side effects by targeting the cannabinoid receptor type 1 (CB1). The research team used computer simulations to design compounds that bind to a hidden pocket on CB1, activating pain relief pathways without leading to tolerance. The compound, known as VIP36, showed effectiveness in mouse models of pain and limited tolerance development over nine days of treatment.

The Future of Pain Management

The global non-opioid pain treatment market is poised for significant growth, driven by increased R&D investments and awareness initiatives. The Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act may facilitate broader access to non-opioid medications, further accelerating this market expansion. As research advances, these innovative pain management approaches could dramatically reduce reliance on opioids and their associated addiction and overdose risks.

While these developments show great promise, further research and clinical trials are necessary to confirm the safety and effectiveness of targeting specific receptors for pain treatment. The approval of suzetrigine has boosted confidence in the pharmaceutical industry’s strategy to target sodium channels for pain relief, potentially paving the way for more innovative pain medications. As this research evolves, it offers hope to millions of chronic pain sufferers for a future with safer, more effective pain management options.

Sources:

https://news.yale.edu/2025/01/21/cannabinoids-offer-new-hope-safe-and-effective-pain-relief

New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis?

https://www.nih.gov/news-events/nih-research-matters/non-opioid-compound-chronic-pain-relief